45337CAM4 Filings — Incyte Corporation

45337CAM4 Filings — Incyte Corporation - FilingSpy

10-Q · Quarter ended Jun 30, 2026 · SEC filing ↗

OPZELURA Medicaid rebate litigation resolved, adding a $246.0M one-time benefit to Q2 2026 net sales.

The OPZELURA Medicaid rebate dispute with CMS ended this quarter, removing a liability that had been building for years. rose 20.9% to $1,272.7M and nearly doubled to $303.3M, driven by a $246.0M from the reversal of the rebate accrual and continued growth from newer products NIKTIMVO and ZYNYZ. The company enters the second half of 2026 with its largest legal overhang cleared and a pipeline catalyst in the upcoming ruxolitinib XR decision.

Key takeaways

Incyte resolved its OPZELURA Medicaid rebate litigation with CMS, recording a $246.0M one-time, in that reversed all previously accrued liabilities through March 31, 2026.
Total rose 20.9% to $1,272.7M, with JAKAFI net sales up 7% to $757.8M on 6% higher paid demand and OPZELURA up 20% to $143.0M on U.S. demand and ex-U.S. uptake.
outside the two largest product lines more than doubled, led by NIKTIMVO at $55.1M, ZYNYZ at $41.4M, and MINJUVI/MONJUVI at $49.2M, reducing the company's reliance on JAKAFI.

Section summaries

Legal Proceedings

Incyte resolved its OPZELURA Medicaid rebate litigation with CMS, recording a $246.0M one-time benefit in Q2 2026.

Incyte reached an agreement with CMS in Q2 2026 to resolve litigation over whether OPZELURA should be treated as a line extension of JAKAFI for Medicaid rebate purposes.
Under the agreement, CMS will not apply the line extension regulation to OPZELURA, and Incyte will no longer accrue for related liabilities.
The resolution resulted in a one-time, non-cash benefit of $246.0 million recorded in , reflecting the reversal of previously established accrual balances through March 31, 2026.
Incyte states it is involved in various patent disputes and litigation related to potential generic or other competition for its products.

45337CAM4

45337CAM4

OPZELURA Medicaid rebate litigation resolved, adding a $246.0M one-time benefit to Q2 2026 net sales.

Key takeaways

Section summaries

Legal Proceedings

What changed

What to watch

Risk Factors